



Ref. No.: EIKO/BSE/2023-24/51

**Date:** 25<sup>th</sup> January, 2024

To,  
Corporate Services Department,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001.

**Scrip Code:** 540204

**Sub: Outcome of the Meeting of the Right Issue Committee of Board of Directors held today on 25<sup>th</sup> January, 2024**

Dear Sir/ Ma'am,

This is to inform you that the Rights Issue of the Company, vide Letter of Offer filed with the Stock Exchange on July 07, 2023, the in-principal Approval of BSE Limited (BSE) vide letter dated May 5, 2023, call notice dated December 26, 2023 and corrigendum to call notice dated January 01, 2024.

With reference to above, Right Issue Committee of the Board has considered and approved the following:

1. To convert 33,53,121 partly paid-up Rights equity shares from Face Value (₹ 3.50 per share to Fully Paid-up shares of Face Value ₹ 10 per share) to the eligible shareholders of the Company pursuant to the payment made with respect to the First and Final Call Notice issued by the Company;
2. To make an application to National Securities Depository Limited ("NSDL") and Central Depository Services (India) Limited ("CDSL") for necessary corporate actions.
3. To avail listing and trading of approvals from BSE Limited ("BSE") pursuant to conversion of partly paid-up shares of Face Value (₹ 3.50 per share to Fully Paid-up shares of Face Value ₹ 10 per share)

The meeting commenced at 03:30 PM and concluded at 04:00 P.M.

Please take the same on your record.

Thanking You,

**Yours Faithfully,**

**For Eiko Lifesciences Limited**

**Jaid Ismail Kojar**  
**Chief Financial Officer**